241 related articles for article (PubMed ID: 19175548)
1. Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin.
Vekeman F; Bookhart BK; White J; McKenzie RS; Duh MS; Piech CT; Lefebvre P
Transfusion; 2009 May; 49(5):895-902. PubMed ID: 19175548
[TBL] [Abstract][Full Text] [Related]
2. Transfusions increase with nationally driven reimbursement changes of erythropoiesis stimulating agents for chemotherapy-induced anemia.
Yu JM; Shord SS; Cuellar S
J Oncol Pharm Pract; 2011 Dec; 17(4):360-5. PubMed ID: 20826550
[TBL] [Abstract][Full Text] [Related]
3. Impact of Centers for Medicare & Medicaid Services national coverage determination on erythropoiesis-stimulating agent and transfusion use in chemotherapy-treated cancer patients.
Arneson TJ; Li S; Gilbertson DT; Bridges KR; Acquavella JF; Collins AJ
Pharmacoepidemiol Drug Saf; 2012 Aug; 21(8):857-64. PubMed ID: 22450901
[TBL] [Abstract][Full Text] [Related]
4. Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)?
Bormanis J; Quirt I; Chang J; Kouroukis CT; MacDonald D; Melosky B; Verma S; Couture F
Crit Rev Oncol Hematol; 2013 Aug; 87(2):132-9. PubMed ID: 23357249
[TBL] [Abstract][Full Text] [Related]
5. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
Arbuckle RB; Griffith NL; Iacovelli LM; Johnson PE; Jorgenson JA; Kloth DD; Lucarelli CD; Muller RJ
Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
[TBL] [Abstract][Full Text] [Related]
6. Update on erythropoiesis-stimulating agents and clinical trials in oncology.
Aapro M; Spivak JL
Oncologist; 2009; 14 Suppl 1():6-15. PubMed ID: 19762512
[TBL] [Abstract][Full Text] [Related]
7. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
Singh AK
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
[TBL] [Abstract][Full Text] [Related]
8. Erythropoiesis-stimulating agents in cancer patients: reflections on safety.
Wauters I; Vansteenkiste J
Expert Rev Clin Pharmacol; 2011 Jul; 4(4):467-76. PubMed ID: 22114856
[TBL] [Abstract][Full Text] [Related]
9. Adherence to guidelines for use of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia: results of a retrospective study of an electronic medical-records database in the United States, 2002-2006.
Luo W; Nordstrom BL; Fraeman K; Nordyke R; Ranganathan G; Linz HE; Winterkorn A; Stokes M; Ross SD; Knopf K
Clin Ther; 2008 Dec; 30(12):2423-35. PubMed ID: 19167601
[TBL] [Abstract][Full Text] [Related]
10. Effect of reimbursement changes on erythropoiesis-stimulating agent utilization and transfusions.
Hess G; Nordyke RJ; Hill J; Hulnick S
Am J Hematol; 2010 Nov; 85(11):838-43. PubMed ID: 20976794
[TBL] [Abstract][Full Text] [Related]
11. Trends in anemia treatment among patients with five non-myeloid malignancies treated with chemotherapy in a large integrated health care delivery system in California, 2000-2013.
Xu L; Xu H; Cannavale K; Sattayapiwat O; Rodriguez R; Page JH; Chao C
Support Care Cancer; 2016 Jul; 24(7):2989-98. PubMed ID: 26872791
[TBL] [Abstract][Full Text] [Related]
12. Blood collection and transfusion in the United States in 1999.
Sullivan MT; Wallace EL
Transfusion; 2005 Feb; 45(2):141-8. PubMed ID: 15660821
[TBL] [Abstract][Full Text] [Related]
13. Trends in Erythropoiesis-stimulating agent use and blood transfusions for chemotherapy-induced anemia throughout FDA's risk evaluation and mitigation strategy lifecycle.
Vega A; Zhang R; Wong HL; Wernecke M; Alexander M; Feng Y; Lo AC; Lufkin B; Ryan Q; Izem R; MaCurdy TE; Kelman JA; Graham DJ
Pharmacoepidemiol Drug Saf; 2021 May; 30(5):626-635. PubMed ID: 33534188
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy-induced anemia: the story of darbepoetin alfa.
Vansteenkiste J; Wauters I; Elliott S; Glaspy J; Hedenus M
Curr Med Res Opin; 2013 Apr; 29(4):325-37. PubMed ID: 23323876
[TBL] [Abstract][Full Text] [Related]
15. Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer.
Juneja V; Keegan P; Gootenberg JE; Rothmann MD; Shen YL; Lee KY; Weiss KD; Pazdur R
Clin Cancer Res; 2008 Jun; 14(11):3242-7. PubMed ID: 18519748
[TBL] [Abstract][Full Text] [Related]
16. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
Nowrousian MR; Dunst J; Vaupel P
Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
[TBL] [Abstract][Full Text] [Related]
17. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.
Aapro MS; Link H
Oncologist; 2008; 13 Suppl 3():33-6. PubMed ID: 18458123
[TBL] [Abstract][Full Text] [Related]
18. Tumor progression associated with erythropoiesis-stimulating agents.
Newland AM; Black CD
Ann Pharmacother; 2008 Dec; 42(12):1865-70. PubMed ID: 19017828
[TBL] [Abstract][Full Text] [Related]
19. Blood collection and transfusion in the United States in 2001.
Sullivan MT; Cotten R; Read EJ; Wallace EL
Transfusion; 2007 Mar; 47(3):385-94. PubMed ID: 17319817
[TBL] [Abstract][Full Text] [Related]
20. Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer- or chemotherapy-induced anemia.
Szucs TD; Blank PR; Schwenkglenks M; Aapro M
Oncology; 2011; 81(1):45-9. PubMed ID: 21921645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
